Avalo Therapeutics announced that Paul Varki has joined the Company as its Chief Legal Officer “We are delighted to have Paul join and grow our leadership team at an exciting time at Avalo following our acquisition and private placement earlier this year,” said Garry A. Neil, MD, CEO and Chairman of the Board at Avalo. “Paul’s deep industry experience will immediately enhance our strategic and legal competencies. Furthermore, we expect his appointment will augment our ability to create and protect value as well as minimize risk as we progress AVTX-009 in hidradenitis suppurativa and plan for the asset’s development in additional autoimmune conditions.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
- Avalo Therapeutics files to sell 22.36M shares of common stock for holders
- Avalo Therapeutics expects cash to fund operations into 2027
- Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
- Oppenheimer Predicts Over 100% Rally for These 2 Healthcare Stocks